Best Practice Advice Issued for Hep B Vaccination, Screening

Share this content:
Best Practice Advice Issued for Hep B Vaccination, Screening
Best Practice Advice Issued for Hep B Vaccination, Screening

TUESDAY, Nov. 21, 2017 (HealthDay News) -- Best practice advice statements from the American College of Physicians and the U.S. Centers for Disease Control and Prevention, published online Nov. 21 in the Annals of Internal Medicine, encourage hepatitis B virus (HBV) screening in high-risk populations, vaccination of all unvaccinated at-risk adults, and linkage to care for HBV-positive patients.

To develop the best practice advice statements, Winston E. Abara, M.D., Ph.D., from the CDC in Atlanta, and colleagues conducted a narrative literature review of clinical guidelines, systematic reviews, randomized trials, and intervention studies on HBV vaccination, screening, and linkage to care.

The authors note that all unvaccinated adults at risk for infection due to sexual, percutaneous, or mucosal exposure; health care and public safety workers at risk for blood exposure; adults with chronic liver disease, end-stage renal disease, or HIV infection; travelers to HBV-endemic regions; and adults seeking protection from HBV infection should be vaccinated. High-risk persons, including persons born in countries with 2 percent or higher HBV prevalence, men who have sex with men, injection drug users, HIV-positive individuals, and household and sexual contacts of HBV-infected persons, should undergo screening for HBV. All patients identified with HBV (hepatitis B surface antigen-positive) should be provided with or referred to post-test counseling and hepatitis B-directed care.

"The best practice advice statements in this article amplify and complement existing clinical guidelines by reiterating the importance of hepatitis B vaccination and screening in at-risk persons and linking infected persons to care," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »